Information Provided By: 
Fly News Breaks for March 31, 2016
JAZZ
Mar 31, 2016 | 07:33 EDT
UBS lowered its price target on Jazz Pharmaceuticals to $162 from $178 following FDA approval of Defitelio for severe hepatic VOD. The firm said approval was expected but it adds another growth driver by helping to diversify away from Xyrem. The price target was lowered to reflect the sector's change in equity risk premium. UBS maintained its Buy rating on Jazz Pharmaceutical shares.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
